United States-based Bon Secours Mercy Health, a Catholic health care system, has collaborated with United States-based Lirio LLC, a behavioural engagement solution, it was reported yesterday.
The strategic partnership was announced at the 38th annual JP Morgan Healthcare Conference and was initiated by a direct investment from Bon Secours Mercy Health in Lirio's behaviour change AI platform. John Starcher, president and CEO of Bon Secours Mercy Health will join Lirio's board of directors.
Both firms will co-develop new behaviour change programs that influence health decision-making for those at risk for chronic diseases, such as diabetes and hypertension. These programs will gradually be marketed and sold to other health systems globally under commercial terms agreed to between both parties. Bon Secours Mercy Health will license and install present Lirio behaviour change programs, such as women's health programs and programs that encourage the use of digital engagement tools like patient portals.
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin